S-2P

S-2P is a stabilized spike protein COVID-19 vaccine antigen, or SARS-CoV-2 S-2P protein immunogen. It was originally co-developed by researchers at the U.S. National Institutes of Health and the University of Texas at Austin. This antigen is designed to elicit an immune response against SARS-CoV-2, serving as the active component in COVID-19 vaccines. It is being developed for delivery via various methods, including an intramuscular version and as part of a combined vaccine delivered through a microneedle patch platform.

Other names

stabilized spike protein COVID-19 vaccine antigenSARS-CoV-2 S-2P protein immunogenSARS-CoV2 S-2P protein immunogenSARS-CoV 2 S-2P protein immunogen